Vonoprazan is noninferior to proton pump inhibitors in bismuth‐containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis
Journal of Digestive Diseases · 2023
DOI: 10.1111/1751-2980.13166 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Digestive Diseases, 2023. Verfasst von Juan Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Taishan Scholars Program of Shandong Province and the National Clinical Research Center for Digestive Diseases Supporting Technology Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This study aimed to evaluate the efficacy and safety of vonoprazan (VPZ) versus proton pump inhibitor (PPI) in clarithromycin‐based bismuth‐containing quadruple therapy (C‐BQT) for the treatment of Helicobacter pylori ( H. pylori ) eradication.
Methods
Medical records of patients in whom H. pylori was eradicated between 1 July 2018 and 31 December 2021 were retrieved retrospectively from the Outpatient Unit of Qilu Hospital. Efficacy, safety, and compliance were compared between VPZ‐based and PPI‐based C‐BQT, containing vonoprazan 20 mg or proton pump inhibitors (lansoprazole 30 mg or esomeprazole 20 mg), bismuth 220 or 200 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, twice daily for 2 weeks by 1:1 propensity score matching analysis. The trial was registed on ClinicalTrials.gov (registration no. NCT05301725).
Results
The H. pylori eradication rates of VPZ‐based and PPI‐based therapies were 88.8% (151/170) and 87.6% (149/170) in the intention‐to‐treat analysis, 94.1% (144/153) and 91.1% (144/158) in the per‐protocol analysis, respectively. The noninferiority of VPZ to PPI was confirmed in all analyses ( P < 0.001). The incidence of adverse events was 30.0% (51/170) and 27.1% (46/170) in the VPZ‐based and PPI‐based groups, respectively. VPZ‐based and PPI‐based therapies were well tolerated and showed good patient compliance without significant differences.
Conclusions
VPZ‐based therapy resulted in a satisfactory eradication rate and was well tolerated for H. pylori eradication, which are comparable to PPIs in C‐BQT as a first‐line treatment for H. pylori infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China.
- Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China.
ORCID-Profile: Yue Yue Li, Xiu Li Zuo, Yan Qing Li
Förderung
- Taishan Scholars Program of Shandong Province and the National Clinical Research Center for Digestive Diseases Supporting Technology Project
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Li, Y. Y., Lin, M. J., Liu, J., Lin, B. S., Ding, Y. M., Wan, M., Zhang, W. L., Kong, Q. Z., Wang, S. T., Mu, Y. J., Duan, M., Han, Z. X., Zuo, X. L., & Li, Y. Q. (2023). Vonoprazan is noninferior to proton pump inhibitors in bismuth‐containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13166
Vancouver
Wang J, Li YY, Lin MJ, Liu J, Lin BS, Ding YM, et al. Vonoprazan is noninferior to proton pump inhibitors in bismuth‐containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis. Journal of Digestive Diseases. 2023. doi:10.1111/1751-2980.13166
BibTeX
@article{Wang2023,
author = {Wang, Juan and Li, Yue Yue and Lin, Min Juan and Liu, Jing and Lin, Bo Shen and Ding, Yu Ming and Wan, Meng and Zhang, Wen Lin and Kong, Qing Zhou and Wang, Shao Tong and Mu, Yi Jun and Duan, Miao and Han, Zhong Xue and Zuo, Xiu Li and Li, Yan Qing},
title = {Vonoprazan is noninferior to proton pump inhibitors in bismuth‐containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis},
journal = {Journal of Digestive Diseases},
year = {2023},
doi = {10.1111/1751-2980.13166}
}
EUVIMED